Oligomerix
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Westchester Park Dr Ste 208, White Pla...Phone Number
(917) 912-4088Website
www.oligomerix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer's disease. The company's drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies nearing completion for the lead program. Oligomerix's small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, the first step of the tau aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on Twitter and LinkedIn. Oligomerix is seeking strateRead more
Oligomerix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oligomerix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Oligomerix is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Oligomerix
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Oligomerix has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Oligomerix recently announced quarterly report
Product Launch: Get notified when Oligomerix launches new products
Oligomerix, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Oligomerix has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Oligomerix had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Oligomerix
Find 2 more new buyers
Compare Similar Companies to Oligomerix
Compare insights from companies similar to Oligomerix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oligomerix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Oligomerix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Oligomerix.
Oligomerix financials insights
Gather financial insights about Oligomerix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$2M
2013
Unspecified
$1.7M
2022
Series B
$8.3M
Oligomerix Tech Stack
A closer look at the technologies used by Oligomerix
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Promotion
Executive Move
Promotion
Executive Move
Promotion
Executive Move
Oligomerix News & Media
Oligomerix Published Results from a Preclinical Therapeutic Treatment Study on an Oral Experimental Drug in Development for Alzheimer’s and Rare Neurodegenerative Diseases
WHITE PLAINS, N.Y.--(BUSINESS WIRE)-- #alzheimersdisease--Oligomerix published a study showing treatment with OLX-07010 inhibited tau aggregation and motor deficits in an aged mouse model of tauopathy.Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease and Rare Neurodegenerative Diseases
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Data show clinical-stage small molecule therapeutic in development for Alzheimer's and neurodegenerative disorders prevents tau aggregationOligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases today announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010. This lead compound is a novel oral, small molecule inhibitor of tau self-association being assessed for the treatment of Alzheimer’s disease and other neurodegenerativeOligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.” The ‘776 patent further strengthens the company’s intellectual property position and coverage for their
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Oligomerix
Sign Up For FreeTo access detailed company insights
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer's disease. The company's drug discovery platform has identified a pipe... Read More
